A n estimated 5% of women and 3% of men in the United States have subclinical thyroid dysfunction (1) , and approximately 0.5% of the population may have undiagnosed overt thyroid disease (2, 3) . Subclinical thyroid dysfunction is defined as elevated or low results on a thyroid-stimulating hormone (TSH) test (reference range, 0.45 to 4.50 mIU/L) in the setting of normal thyroid hormone levels. Overt thyroid disease is defined by the presence of abnormal thyroid hormone (free thyroxine, with or without triiodothyronine) levels (4, 5) ( Table 1) . In some studies, subclinical hypothyroidism is associated with increased risk for coronary artery disease (6, 7) ; congestive heart failure (8) ; and subclinical hyperthyroidism with increased risk for allcause and coronary heart disease mortality, atrial fibrillation (9) , and decreased bone density (5) . Overt thyroid disease is associated with negative cardiovascular, musculoskeletal, dermatologic, gastrointestinal, and other effects, but clinical manifestations are highly variable and depend on the severity of thyroid abnormalities. Thyroid screening could identify persons with subclinical as well as undiagnosed overt thyroid dysfunction who could potentially benefit from treatment to reduce the risk for adverse health outcomes.
In 2004, the U.S. Preventive Services Task Force (USPSTF) found insufficient evidence to recommend for or against thyroid screening in asymptomatic, nonpregnant adults. Although the USPSTF concluded that sub-USPSTF determined that in addition to subclinical thyroid dysfunction, screening could also identify undiagnosed overt thyroid disease (2, 3) ; therefore, the decision to screen should also consider the potential benefits and harms of identifying and treating undiagnosed overt disease. Therefore, this update differs from previous USPSTF reviews and the 2011 review in that it also addresses identification and treatment of undiagnosed overt thyroid disease.
Study Selection
Two investigators independently evaluated each study at the title or abstract and full-text article stages to determine eligibility for inclusion. We included randomized trials and observational studies of thyroid screening versus no screening in adults (excluding pregnant women) without a history of thyroid dysfunction or obvious goiter, nodules, or symptoms, following the protocol. We also included studies of treatment versus no treatment in adults with subclinical or overt thyroid dysfunction. Screening was based on TSH testing, with follow-up testing of thyroid hormone levels (free thyroxine, with or without triiodothyronine). Studies of patients with subclinical hypothyroidism due to Hashimoto thyroiditis (based on antibody testing) were included if they did not describe enrollment of symptomatic patients. Clinical outcomes were cardiovascular end points (cardiovascular disease, coronary artery disease or congestive heart failure, and atrial fibrillation); fractures; measures of quality of life or cognitive function; and harms, including those related to overreplacement (such as negative effects on bone mineral density or atrial fibrillation). Intermediate outcomes were effects on lipid levels, blood pressure, weight change, and bone mineral density.
We restricted inclusion to English-language articles and excluded studies published only as abstracts. The literature flow diagram is shown in Supplement 3 (available at www.annals.org).
Data Abstraction and Quality Assessment
One investigator abstracted details about the study design, patient population, setting, screening method, interventions, data analysis, and results, and another investigator verified data abstraction for accuracy. Two investigators independently applied criteria developed by the USPSTF to rate the quality of each study as good, fair, or poor (15, 16) . Discrepancies were resolved through a consensus process. For all studies, we evaluated applicability to populations likely to be encountered in primary care screening settings. 
Data Synthesis and Analysis
We assessed the aggregate internal validity (quality) of the body of evidence for each key question (good, fair, or poor) using methods developed by the USPSTF, on the basis of aggregate study quality, precision of estimates, consistency of results among studies, and directness of evidence (15, 16) . A meta-analysis was not performed because of the methodological and clinical diversity among the included studies.
Role of the Funding Source
This research was funded by the Agency for Healthcare Research and Quality (AHRQ) under a contract to support the work of the USPSTF. Investigators worked with USPSTF members and AHRQ staff to develop the scope, analytic framework, and key questions. The funding source had no role in study selection, quality assessment, or data synthesis. Agency for Healthcare Research and Quality staff provided project oversight; reviewed the report to ensure that the analysis met methodological standards; and distributed the draft for peer review, including representatives of professional societies and federal agencies. The investigators are solely responsible for the content and the decision to submit the manuscript for publication.
RESULTS
No study compared clinical benefits or harms in persons screened versus not screened for thyroid dysfunction (the first 2 key questions). We identified 11 trials (in 14 publications) and 1 retrospective cohort study on treatment of subclinical hypothyroidism (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . Two studies examined treatment of subclinical hyperthyroidism but were poor-quality and evaluated intermediate outcomes (32, 33) ; they are discussed in the full report (14) . No study addressed treatment versus no treatment of screen-detected, undiagnosed overt hypothyroidism.
Three trials were rated good-quality (22, 27, 28) , 6 trials (reported in 7 publications) were rated fair-quality (18 -21, 23, 24, 26) , and 4 trials (in 5 publications) were rated poor-quality (17, 30 -33) . The retrospective cohort study was rated fair-quality (29) . Most of the poorquality studies were characterized by poor reporting of methods (such as methods of randomization, allocation concealment, blinding, and reporting of attrition) rather than clearly inadequate methods.
None of the trials were conducted in the United States. The TSH values used to diagnose subclinical thyroid dysfunction at baseline ranged from 4.1 to 11.0 mIU/L. Mean patient ages ranged from 32 years to older than 70 years. Treatment of subclinical hypothyroidism was levothyroxine using different dosing regimens. Study duration ranged from 4 to 12 months, except for the cohort study, which analyzed data with up to a 7.6-year follow-up (29) . Sample sizes in the trials ranged from 14 to 120 patients; the cohort study analyzed 4735 patients (29) . Whereas most studies evaluated a placebo comparator, 3 used a no-treatment comparison (18, 19, 29) .
Three trials (in 4 publications) specifically evaluated screen-detected populations (17, 20, 21, 27) . Most other trials did not clearly report how patients were identified, other than that they were recruited from outpatient clinics. Trials generally reported that patients were newly diagnosed and excluded those with previous thyroid dysfunction or previous receipt of antithyroid medications.
Effectiveness of Treatment of Subclinical Hypothyroidism on Clinical Outcomes

Cardiovascular Events and Mortality
The 2004 USPSTF review (1, 13) included no study on the effects of treatment of subclinical hypothyroidism on risk for cardiac events or death. We identified 1 fair-quality, retrospective cohort study published since the 2004 USPSTF review on the effects of treatment of subclinical hypothyroidism (based on a single TSH level of >5.01 to 10.00 mIU/L) in 4735 persons aged 40 years or older in the United Kingdom on risk for cardiac events (mean follow-up, 7.6 years) (29) ( Table 2 ). On the basis of an a priori categorization, analyses were stratified by age (40 to 70 years vs. >70 years), and analyses of the entire cohort were not reported. Approximately one half of the persons were treated with levothyroxine (mean dose, 75 μg/day).
After adjustment for age, sex, body mass index, socioeconomic status, total cholesterol level, smoking status, history of diabetes mellitus, index serum TSH level, and blood pressure, levothyroxine use versus no treatment was associated with lower risk for fatal or nonfatal ischemic heart disease events (4.2% vs. 6 . Potential limitations include the lack of adjustment for medications to reduce risk for cardiovascular disease, although baseline data suggested no differences between treatment groups.
Quality of Life
The 2004 USPSTF review (1, 13) included 5 trials on the association between treatment of subclinical thyroid dysfunction and quality of life (22, 34 -37) . One trial found treatment of subclinical hypothyroidism associated with better quality of life in patients with recent Graves disease (34) . The other 4 trials found no effects of treatment (22, (35) (36) (37) . However, 3 of these trials would have been excluded from this update because patients were previously treated for thyroid dysfunction (34, 36) or because it enrolled mostly patients who were euthyroid (37).
We identified 5 trials (3 good-quality [22, 27, 28] , 1 fair-quality [21] , and 1 poor-quality [17] ) published since the 2004 USPSTF review on effects of treatment of subclinical hypothyroidism (TSH thresholds varied from >3.5 to >5.5 mIU/L) using various doses of levothyroxine (mean, 50.0 to 109.7 μg/day) on measures of quality of life (Short Form-36 Health Survey, the General Health Questionnaire-30, the Beck Depression Inventory, the Hospital Anxiety and Depression Scale, and the Underactive Thyroid-Dependent Quality of Life Questionnaire) ( Table 3) . Sample sizes were less than 100 in all trials, mean age ranged from 45 to 74 years, and follow-up ranged from 4 to 12 months. No differences were found between treatment and placebo in any study. Three trials evaluated screen-detected populations (17, 21, 27) .
Cognitive Function
Two trials included in the previous USPSTF review evaluated effects of treatment of subclinical hypothyroidism on cognitive function (35, 37) . One trial that also included patients who were euthyroid (37) found no effect, and the second trial found a statistically significant but clinically small improvement in memory using a composite outcome in persons older than 55 years (35) .
We identified 1 good-quality (27) and 1 fair-quality (21) trial published since the last USPSTF review that found no association between treatment with levothyroxine for subclinical hypothyroidism (defined as TSH levels >3.5 and <10 mIU/L [21] or TSH levels >5.5 mIU/L [27] ) versus placebo and various measures of cognitive function after 12 months ( Table 3) . Both studies seemed to evaluate screen-detected populations. Mean ages were 62 to 63 years in 1 study (69 patients) (21) and 74 years in the other (94 patients) (27) . The good-quality study (27) 
Effectiveness of Treatment of Subclinical Hypothyroidism on Intermediate Outcomes
Blood Pressure
The 2004 USPSTF review (1, 13) included no study on the effect of treatment of subclinical hypothyroidism on blood pressure.
We identified 1 good-quality (28) and 2 fair-quality (24, 26) trials that found no effects on blood pressure between treatment versus no treatment of subclinical hypothyroidism (defined as TSH levels >3.6 mIU/L [24] or >4.0 mIU/L [28] , or TSH levels greater than the normal limit [26] ). Differences between treatment and placebo groups in mean systolic blood pressure ranged from Ϫ3 to Ϫ2 mm Hg and in mean diastolic blood pressure ranged from Ϫ3 to 0 mm Hg (Supplement 4, available at www.annals.org).
Lipids
The previous USPSTF review included 7 trials on the effect of treatment of subclinical hypothyroidism and effects on lipid profiles (22, 25, 34 -36, 38, 39) . Six trials found no improvement in lipid variables (22, 25, 34 -36, 39) , with 1 poor-quality trial in euthyroid patients reporting approximately a 5% improvement in low-density lipoprotein (LDL) cholesterol levels with 50 μg/day versus 25 μg/day of levothyroxine (38) .
Total Cholesterol
We identified 2 good-quality trials (22, 28) , 6 fairquality trials (18, 19, 23, 24, 26) , and 1 poor-quality (30, 31) trial published since the 2004 USPSTF review on the effects of treatment of subclinical hypothyroidism on total cholesterol levels. Thyroid-stimulating hormone thresholds varied from greater than 3.6 to greater than 5 mIU/L, or "greater than the upper limit of normal" (26) (Supplement 4). In the 8 good-and fair-quality trials, differences between treatment and no treatment in mean total cholesterol levels ranged from Ϫ0.7 to 0 mmol/L (Ϫ28 to 0 mg/dL). Three of the trials (45, 100, and 120 patients) reported statistically significant differences in mean total cholesterol levels of Ϫ0.3 mmol/L (Ϫ12 mg/dL) (P < 0.03) (23), Ϫ0.7 mmol/L (Ϫ28 mg/ dL) (P = 0.03) (24) , and Ϫ0.3 mmol/L (Ϫ12 mg/dL) (P < 0.001) (28) . The poor-quality trial found treatment associated with slightly lower total cholesterol levels (difference in means, Ϫ0.2 mmol/L [Ϫ6 mg/dL], P = 0.03) (30, 31) .
Low-Density Lipoprotein Cholesterol
Two good-quality trials (22, 28), 6 fair-quality trials (18 -20, 23, 24, 26) , and 1 poor-quality (30, 31) trial published since the previous USPSTF review evaluated the effect of treatment of subclinical hypothyroidism on LDL cholesterol levels (Supplement 4). In the 8 goodand fair-quality trials, differences between treatment and no treatment in mean LDL cholesterol levels ranged from Ϫ0.6 to 0.1 mmol/L (Ϫ22 to 2 mg/dL). Three of the trials (45, 100, and 120 patients) reported statistically significant differences in mean LDL cholesterol levels of Ϫ0.2 mmol/L (Ϫ8 mg/dL) (P < 0.001) (23), Ϫ0.6 mmol/L (Ϫ22 mg/dL) (P = 0.03) (24) , and Ϫ0.3 mmol/L (Ϫ12 mg/dL) (P < 0.001) (28) . The poorquality trial found treatment associated with slightly lower LDL cholesterol levels (difference in means, Ϫ0.3 mmol/L [Ϫ12 mg/dL], P = 0.02) (30, 31) .
High-Density Lipoprotein Cholesterol
We identified 2 good-quality trials (22, 28), 6 fairquality trials (18 -20, 23, 24, 26) , and 1 poor-quality (30, 31) trial published since the previous USPSTF review on the effect of treatment of subclinical hypothyroidism on high-density lipoprotein cholesterol levels (Supplement 4). In the 8 good-and fair-quality trials, differences between treatment and no treatment in mean highdensity lipoprotein cholesterol levels ranged from Ϫ0.1 to 0.1 mmol/L (Ϫ4 to 4 mg/dL). None of the trials found a significant difference between treatment and control groups in high-density lipoprotein cholesterol levels.
Triglycerides
We identified 2 good-quality trials (22, 28), 6 fairquality trials (18 -20, 23, 24, 26) , and 1 poor-quality (30, 31) trial on the effect of treatment of subclinical hypothyroidism on triglyceride levels (Supplement 4). In the 8 good-and fair-quality trials, differences in means ranged from Ϫ0.4 to 0.1 mmol/L (Ϫ32 to 11 mg/dL). None of the trials found a significant difference between treatment and control in triglyceride values.
Body Mass Index or Weight
No study in the 2004 USPSTF review assessed effects of treatment of subclinical thyroid dysfunction on body mass index or weight.
We identified 2 good-quality (22, 28) and 4 fairquality (19, 20, 24, 26) trials published since the 2004 USPSTF review on the effect of treatment of subclinical hypothyroidism (TSH thresholds varied from >3.5 to >5 mIU/L, or "greater than the normal range" [26] ) on body mass index or weight (Supplement 4). None of the trials found a significant difference between treatment and control groups in body mass index or weight. Of 5 trials reporting body mass index, differences between treatment and placebo groups ranged from Ϫ1 to 1 kg/m 2 . Of the 2 trials reporting weight, 1 found a difference in means of Ϫ1 kg (28) and 1 found a 0.1% difference in lean body weight (22) .
Harms of Treatment of Subclinical Hypothyroidism
The 2004 USPSTF report found very limited evidence on harms related to treatment of subclinical hypothyroidism. One good-quality trial of patients who developed subclinical hypothyroidism after treatment of Graves disease found that 4 of 17 persons randomly assigned to levothyroxine felt worse than 6 of 15 persons given placebo (P = 0.33) (34) . Other studies reported 1 case of angina (35), 1 case of atrial fibrillation (35) , decreased anxiety scores (22) , decreased Short Form-36 Health Survey vitality scores (37), and 2 withdrawals due to adverse events (39) .
Five trials (in 6 publications) published since the 2004 USPSTF review reported harms, but they were poorly assessed and reported, precluding reliable conclusions (17, 26 -28, 30, 31) . In addition, the studies were not designed or powered to assess long-term or serious harms, or harms related to overtreatment. One study reported "no indication of harms" (17) , and another study stated that none of the patients reported adverse events requiring withdrawal or dose reduction (26) . One study reported no difference between treatment versus placebo in risk for withdrawal due to adverse events after 12 months (9.6% vs. 14.3%; P = 0.49) (27) . Two other trials (100 and 60 patients) reported 0 (28) or 2 (30, 31) withdrawals due to adverse events in patients with subclinical hypothyroidism.
DISCUSSION
The evidence we reviewed is summarized in Table  4 . As in the 2004 USPSTF review, we found no direct evidence on effects of thyroid screening versus no screening on clinical outcomes. The scope of this update was expanded to include detection and treatment Levothyroxine associated with no effect on systolic blood pressure (difference range, −3 to −2 mm Hg) or diastolic blood pressure (difference range, −3 to 0 mm Hg)
Poor
Continued on following page of screen-detected, undiagnosed overt thyroid disease, but we found no studies of treatment versus no treatment, probably because treatment is considered the standard of care for this condition. Evidence on benefits and harms of treatment was largely restricted to patients with subclinical hypothyroidism. Despite the potential association between subclinical hypothyroidism and cardiovascular disease and congestive heart failure (6 -8) , there is no clear evidence that treatment improves clinical outcomes. Although 1 fair-quality retrospective cohort study found treatment of subclinical hypothyroidism associated with decreased risk for cardiac events, cancer, and all-cause mortality in adults aged 40 to 70 years (29) , it was an observational study with potential methodological limitations, including a lack of adjustment for some important confounders. As in the 2004 USPSTF review, evidence from newer trials found that treatment of subclinical hypothyroidism was not associated with clear improvement in quality of life or measures of cognitive function (17, 21, 22, 27, 28) . Findings about intermediate outcomes were also consistent with the 2004 USP-STF review. Trials found no clear benefits of treatment of subclinical hypothyroidism on blood pressure, bone mineral density, or body mass index. Although treatment of subclinical hypothyroidism may have some beneficial effects on total cholesterol and LDL cholesterol levels, differences were small and of uncertain clinical significance (range, Ϫ0.7 to 0 mmol/L [Ϫ28 to 0 mg/dL] for total cholesterol levels and Ϫ0.6 to 0.1 mmol/L [Ϫ22 to 2 mg/dL] for LDL cholesterol levels) and were not statistically significant in most studies (18 -20, 22-26, 28, 30, 31) . No study evaluated treatment of subclinical hypothyroidism with greater TSH Poor BMI = body mass index; HDL = high-density lipoprotein; KQ = key question; LDL = low-density lipoprotein; NA = not applicable; RCT = randomized, controlled trial; TSH = thyroid-stimulating hormone. * Hyperthyroidism results are summarized in the full report (14) . † The aggregate internal validity rating of the body of the evidence based on study limitations, precision, consistency, and applicability. ‡ Asymptomatic or mildly symptomatic patients with biochemically overt thyroid disease. levels, which may be associated with increased risk for adverse clinical outcomes. As detailed in the full report (14) , only 2 poorquality trials evaluated effects of treatment of subclinical hyperthyroidism on intermediate outcomes (32, 33) . Although a recent systematic review of observational studies found that subclinical hyperthyroidism may be associated with an increased risk for fractures, it only found trends, not statistically significant effects (40) .
The harms of screening remain poorly studied and sparsely reported. Potential harms of screening for subclinical hypothyroidism include false-positive test results, anxiety related to test results, and harms of treatment (including overreplacement or overtreatment), but evidence is too limited to estimate effects on any of these outcomes. Two prospective cohort studies suggest that approximately 40% of persons with subclinical hypothyroidism were biochemically euthyroid after 3 years of watchful waiting, suggesting that overdiagnosis and subsequent overtreatment could be an issue (41, 42) .
Our review has several limitations. We did not include non-English-language articles, and we could not assess for publication bias using graphical or statistical methods because of small numbers of studies (43) . Limitations of the evidence include methodological shortcomings in most studies, the lack of studies conducted in the United States, small sample sizes, relatively brief duration of follow-up (4 to 12 months), and variability in criteria used to define thyroid dysfunction and in the treatment regimens. The applicability of the evidence on treatment is also uncertain because few trials clearly evaluated screen-detected populations or described how patients were identified (17, 20, 21, 27) .
Additional research may help clarify the benefits and harms of thyroid screening. To better understand potential benefits and harms of thyroid screening, research is needed on the prevalence of unrecognized overt thyroid disease and on effects of treatment in such patients. Trials that evaluate clinical outcomes associated with thyroid screening versus no screening would provide the most direct evidence but may require large samples and long duration of follow-up to evaluate cardiovascular outcomes and mortality rates. Therefore, it may be prudent to first conduct welldesigned trials of treatment of subclinical hypothyroidism versus placebo or no treatment in screen-detected populations because determining treatment efficiency is a prerequisite for effective screening interventions. Observational studies could help provide important information on effects of screening and treatment but should be conducted in well-defined populations and account for important confounders (such as patient demographic characteristics, medical and psychiatric comorbid conditions, risk factors for cardiovascular disease, and concomitant medication use) in their design and analysis. Another emerging area with implications for screening is research suggesting that subclinical hypothyroidism may be protective in older persons (41, 44, 45) and that the reference ranges for TSH should be adjusted upward in older adults (46, 47) . Additional research to clarify criteria for abnormal thyroid function would have important implications for defining the target populations and understanding the effect of screening.
In conclusion, screening can identify patients with subclinical thyroid dysfunction or undiagnosed overt thyroid disease, but direct evidence on benefits and harms of screening versus no screening remains unavailable. Trials of treatment of subclinical hypothyroidism suggest potential beneficial effects on total cholesterol and LDL cholesterol levels, but results were inconsistent and the magnitude of effect was of uncertain clinical significance. The only study showing a beneficial effect of treatment on cardiovascular events was observational and susceptible to residual confounding. Trials on the effects of treatment of subclinical hypothyroidism on other clinical and intermediate outcomes showed no clear beneficial effects, and data on harms were poor. More research is needed to understand effects of treatment of subclinical thyroid dysfunction and screen-detected, undiagnosed overt thyroid disease. 
